Brivaracetam

Benefits at a glance

  • Product is already successfully developed for US
  • Established global Supplier
  • Day 1 launch possible

Product details

Indication:

Adjunctive therapy in the treatment of partial onset seizures in adults, adolescents and children from 2 years of age with epilepsy.

Strengths

25 mg + 50 mg + 75 mg + 100 mg

Dosage form

Film coated tablet

API

Brivaracetam

Dossier available

Q3/2023

Turnover

82 Mio. € (IQVIA 2021 – EU)

Status

  • Development Kick-off
  • Formulation Development
  • Prototype
  • Pilot BE
  • Scale Up
  • Pivotal BE
  • 6 M Stability
  • Dossier
  • EU-Approval

Summary

With our Brivaracetam-Dossier, we can offer access to a product backed by a reliable supply chain.

With the product being based on a completed and approved US-development, we are very confident about its success and timely completion.

With approximately 50 million people globally suffering from Epilepsy, Brivaracetam can provide an effective treatment option, with the potential to unlock significant market potential.

 

Your Contact

Heike Sagi

Heike Sagi

Business Development & Licensing
Senior Director

Midas Pharma GmbH
Rheinstraße 49
55218 Ingelheim
Germany
  • Disclaimer

    The exploitation, including the development, sale and offer for sale of products and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC. This document, therefore, does not and shall not constitute an offer for sale for the product in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for the information provided in this document as well as for damages resulting from or arising out of the use of the product and related process for purposes other than research and development in compliance with applicable laws.

     

Share this page